- Home
- NRXP vs INKT Comparison
NRXP vs INKT Comparison
Compare NRXP & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRXP | INKT |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.5M | 51.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NRXP | INKT |
|---|---|---|
| Price | $2.07 | $12.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $30.50 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 452.8K | 19.7K |
| Earning Date | 11-17-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $242,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $643.59 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.17 | $4.56 |
| 52 Week High | $6.01 | $76.00 |
Technical Indicators
Market Signals| Indicator | NRXP | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 37.62 | 51.40 |
| Support Level | $2.22 | $11.48 |
| Resistance Level | $2.39 | $13.34 |
| Average True Range (ATR) | 0.15 | 0.84 |
| MACD | 0.01 | 0.27 |
| Stochastic Oscillator | 4.26 | 67.49 |
Price Performance
Historical ComparisonAbout NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.